China's XtalPi H1 revenue falls on absence of prior-year licensing payment

XtalPi Holdings

19/08/2026 11:22

Overview
China AI drug discovery firm's H1 revenue fell yr/yr due to prior period's large licensing payment
Company posted net loss and higher R&D expenses as investment in technology increased
Excluding last year's one-off, underlying revenue rose 73.8% and AI4S Intelligent Solutions grew strongly

Outlook
Company expects short-term growth from increased AI-driven drug discovery demand
XtalPi sees stable revenue from platform services and asset monetization in the medium term
Company expects long-term benefits from industry shift to data- and intelligence-driven R+D

Result Drivers
ONE-OFF LICENSING PAYMENT - Revenue fell yr/yr due to absence of large upfront payment recognized in prior period from a major pipeline licensing project
AI4S INTELLIGENT SOLUTIONS GROWTH - Revenue from AI4S Intelligent Solutions rose 136.4% yr/yr, with both Intelligent Robotic Labs and Intelligent Services maintaining rapid growth
R&D INVESTMENT – R&D expenses rose 66.0% as XtalPi invested in autonomous labs, agentic systems, pipeline programs and multimodal platforms

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 393.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for XtalPi Holdings Ltd is HK$10.80, about 49.4% above its August 19 closing price of HK$7.23
The stock recently traded at 1,399 times the next 12-month earnings vs. a P/E of 731 three months ago

Reuters Recommended Reads
Aug 18 - China's GenScript Biotech H1 revenue rises on AI drug discovery
Aug 18 - Baidu CEO vows to return Ernie to AI frontier as revenue miss sinks shares
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-19/adfb5061-8ecf-4d28-9b31-bb249f50d362.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)